Anthropic Launches Claude Science AI Workbench, Aims to Develop Its Own Drugs

What Happens Next

• →Mid-tier biotech firms with limited internal compute infrastructure become early adopters of Claude Science, shifting competitive dynamics away from large pharma companies that built proprietary AI pipelines.
• →Samsung's foundry division gains leverage in AI chip negotiations beyond Anthropic, as the partnership signals Samsung's viability as an alternative to TSMC for custom AI silicon.
• →Traditional pharmaceutical companies begin acquiring or partnering with AI-native drug discovery startups at elevated valuations to close the capability gap Anthropic's entry exposes.
• →Venture capital funding flows disproportionately toward startups building vertical AI applications in regulated industries (pharma, materials science), mirroring Anthropic's applied-science playbook.

Near-term: Biotech and AI-adjacent companies initiate pilot programs with Claude Science within 90 days, while Samsung-Anthropic chip negotiations draw competing bids from GlobalFoundries and Intel Foundry Services. Long-term: Anthropic's vertical integration across chips, models, and drug discovery creates a new competitive category — the AI-native pharmaceutical company — forcing regulators to develop new frameworks for AI-originated drug submissions and IP ownership.